

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	06267.0132-00000
-------	---	----	---	------------------------	------------------

**Complete if Known**

Application Number	10/552,892
Filing Date	November 26, 2007
First Named Inventor	Antti HAAPALINNA et al.
Art Unit	1614
Examiner Name	S. M. Rao

**U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS**

Examiner Initials	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>

**NONPATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
	1	Bowyer, J.F. et al., "Brain Region-Specific Neurodegenerative Profiles Showing The Relative Importance Of Amphetamine Dose, Hyperthermia, Seizures, And The Blood-Brain Barrier," <i>Ann. NY Acad. Sci.</i> (2008) 1139:127-39.	
	2	Gellman R. L. et al., "α2 receptors mediate an endogenous noradrenergic suppression of kindling development," <i>J. Pharmacol. Exp. Ther.</i> (1987) 241(3):891-8.	
	3	Haapalinna, A. et al., "Evaluation Of The Effects Of A Specific Alpha 2-Adrenoceptor Antagonist, Atipamezole, On α1- And α2-Adrenoceptor Subtype Binding, Brain Neurochemistry And Behaviour In Comparison With Yohimbine," <i>Naunyn-Schmiedebergs Arch. Pharmacol.</i> (1997) 356(5):570-82.	
	4	Halonen, T. et al., "α2-Adrenoceptor Agonist, Dexmedetomidine, Protects Against Kainic Acid-Induced Convulsions And Neuronal Damage," <i>Brain Res.</i> (1995) 693:217-24.	
	5	Hanson, G. R. et al., "Distinct Features Of Seizures Induced By Cocaine And Amphetamine Analogs," <i>Eur. J Pharmacol.</i> (1999) 377(2-3):167-73.	
	6	Hesse, S. and Werner, C., "Poststroke Motor Dysfunction And Spasticity: Novel Pharmacological And Physical Treatment Strategies," <i>CNS Drugs</i> (2003) 17(15):1093-107.	
	7	Jolkonen, J. et al., "Neuroprotection By The α2-Adrenoceptor Agonist, Dexmedetomidine, In Rat Focal Cerebral Ischemia," <i>Eur. J Pharmacol.</i> (1999) 372(1):31-6.	
	8	Martinsson, L. and Eksborg, S., "Drugs For Stroke Recovery: The Example Of Amphetamines," <i>Drugs Aging</i> (2004) 21(2):67-79.	
	9	Naidech A. M. et al., "Phenytoin Exposure Is Associated With Functional And Cognitive Disability After Subarachnoid Hemorrhage," <i>Stroke</i> (2005) 36(3):583-7.	
	10	Pitkänen. A., et al., "Atipamezole, An Alpha(2)-Adrenoceptor Antagonist, Has Disease Modifying Effects On Epileptogenesis In Rats," <i>Epilepsy Res.</i> (2004) 61(1-3):119-40	
	11	Shouse M. N. et al., "The α2-Adrenoreceptor Agonist Clonidine Suppresses Seizures, Whereas The α2-Adrenoreceptor Antagonist Idazoxan Promotes Seizures In Amygdala-kindled Kittens: A Comparison Of Amygdala And Pontine Microinfusion Effects," <i>Epilepsia</i> (1996) 37(8):709-17.	
	12	Stringer, J. L. et al., "Cholinergic And Adrenergic Agents Modify The Initiation And Termination Of Epileptic Discharges In The Dentate Gyrus," <i>Neuropharmacology</i> (1991) 30(1):59-65.	
	13	Zagnoni, P. G., Albano, C., "Psychostimulants And Epilepsy," <i>Epilepsia</i> (2002) 43 Suppl 2:28-31.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.